Investors tracking the rapid buildout of power generation and data-center infrastructure often weigh multiple construction and engineering names against one another. AGX and ECG both sit squarely in this thematic space, yet they represent different risk and return profiles. This stock comparison examines their business models, recent momentum, and market positioning to help traders and long-term investors evaluate which profile may be better suited to current conditions. Because both stocks have experienced notable volatility in recent months, the discussion emphasizes relative performance and stability rather than any single-day move.
AGX, Argan, Inc., is an engineering, procurement, and construction (EPC) firm serving the power generation, industrial, and telecommunications infrastructure markets. The company is best known for building and maintaining energy facilities, a niche that has drawn significant investor attention amid rising electricity demand tied to artificial intelligence data centers.
In its most recently reported fiscal year, Argan grew revenues roughly 8% while nearly doubling its project backlog to approximately $2.9 billion, a record that signals multi-year revenue visibility. The company also holds a notably clean balance sheet, with more than $1 billion in cash and investments and essentially no debt. Profitability is strong for the sector, with a net margin in the mid-teens and return on equity (ROE) near 40%.
Despite these fundamentals, AGX has pulled back sharply from its 52-week high in recent market activity, with a three-month decline in the mid-double digits. The drawdown reflects broader profit-taking in high-multiple construction names and elevated valuation sensitivity rather than a deterioration in the underlying order book. The stock's relatively low beta of roughly 0.6 has historically meant more modest swings than many peers.
ECG, Everus Construction Group, Inc., provides electrical, mechanical, and transmission-and-distribution contracting services across the United States. Spun off from its former parent in late 2024, Everus has grown quickly on demand from utilities, renewables, and hyperscale data-center projects.
Recent results have been strong on the top line: the company reported quarterly revenue growth of roughly 40% year over year, driven by broad end-market demand and acquisitions. Its backlog reached a record of approximately $5.5 billion, and management raised full-year guidance. Earnings per share and net income also expanded substantially.
At the same time, ECG operates a thinner-margin business, with a net margin in the single digits, and it carries more balance-sheet leverage than AGX. The stock also exhibits higher volatility, reflected in a beta well above one. Following a strong run earlier in the year, ECG has declined significantly from its peak in recent weeks, as investors reassessed valuation and margin durability across construction names.
Tickeron operates a large ecosystem of AI trading bots that monitor and trade thousands of different tickers across a wide range of strategies, timeframes, and risk profiles. Because no single approach suits every market environment, Tickeron curates a dedicated Trending AI Robots section to highlight the strategies best aligned with current conditions. These bots vary considerably in trading style, holding period, performance statistics, and the sets of tickers they follow, giving users a way to compare automated approaches side by side. Investors and traders interested in how systematic, data-driven strategies are navigating names like AGX and ECG can explore the curated list at Trending AI Robots.
The clearest contrast between these two companies lies in how they generate value. AGX is an asset-light EPC specialist with high margins, a debt-free balance sheet, and a concentrated but high-value power-construction order book. ECG is a broader contractor with faster growth and a larger backlog, but thinner margins and a higher debt-to-equity ratio.
On momentum, ECG has delivered more rapid revenue and earnings expansion, yet its higher beta means its share price swings more violently, and it has given back much of its earlier-year gains. AGX has grown more moderately but with greater margin stability and substantially lower volatility.
Risk factors also diverge. ECG faces concentration risk from data-center and hyperscale customers, plus execution risk inherent to thin-margin contracting. AGX is exposed to project timing and power-market cycles but is cushioned by cash reserves and minimal debt. From a market-sentiment standpoint, both are sensitive to the same macro theme, but their distinct profiles create a genuine trade-off between growth and stability.
Weighing trend consistency, balance-sheet strength, margin quality, and relative volatility, Tickeron's AI framework would currently favor AGX. The model tends to reward a debt-free balance sheet, higher and more stable margins, and a lower-beta price profile during periods of market-wide repricing. While ECG offers stronger growth and a larger backlog, its thinner margins and higher volatility introduce additional uncertainty that the framework weighs against it in the present environment. This assessment is probabilistic and reflects current observable conditions rather than a definitive forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Aroon Indicator for AGX entered a downward trend on November 16, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 112 similar instances where the Aroon Indicator formed such a pattern. In 76 of the 112 cases the stock moved lower. This puts the odds of a downward move at 68%.
The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AGX as a result. In 53 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 56%.
The Moving Average Convergence Divergence Histogram (MACD) for AGX turned negative on November 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 28 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 54%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AGX's RSI Indicator exited the oversold zone, 12 of 18 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 37 of 49 cases where AGX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
Following a +17.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where AGX advanced for three days, in 261 of 344 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
AGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron SMR rating for this company is 26 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.681) is normal, around the industry mean (15.143). P/E Ratio (21.562) is within average values for comparable stocks, (167.534). Projected Growth (PEG Ratio) (0.030) is also within normal values, averaging (3.522). Dividend Yield (0.010) settles around the average of (0.215) among similar stocks. P/S Ratio (4.697) is also within normal values, averaging (2.886).
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AGX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. AGX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The RSI Oscillator for ECG moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 5 similar instances when the indicator left oversold territory. In 5 of the 5 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 15 of 17 cases where ECG's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for ECG just turned positive on November 18, 2026. Looking at past instances where ECG's MACD turned positive, the stock continued to rise in 19 of 22 cases over the following month. The odds of a continued upward trend are 86%.
Following a +3.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where ECG advanced for three days, in 106 of 124 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
ECG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ECG as a result. In 26 of 41 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 63%.
The 10-day moving average for ECG crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 4 of 4 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ECG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
The Aroon Indicator for ECG entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 26 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.059) is normal, around the industry mean (15.143). P/E Ratio (15.382) is within average values for comparable stocks, (167.534). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.522). Dividend Yield (0.000) settles around the average of (0.215) among similar stocks. P/S Ratio (1.335) is also within normal values, averaging (2.886).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. ECG’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 85 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ECG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.
AGX | ||
|---|---|---|
OUTLOOK RATING 1..100 | 74 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 66 Overvalued | |
PROFIT vs RISK RATING 1..100 | 67 | |
SMR RATING 1..100 | 26 | |
PRICE GROWTH RATING 1..100 | 80 | |
P/E GROWTH RATING 1..100 | 91 | |
SEASONALITY SCORE 1..100 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| AGX | ECG | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 67% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 76% | 1 day ago 88% |
| Momentum ODDS (%) | 1 day ago 56% | 1 day ago 63% |
| MACD ODDS (%) | 1 day ago 54% | 1 day ago 86% |
| TrendWeek ODDS (%) | 1 day ago 59% | 1 day ago 69% |
| TrendMonth ODDS (%) | 1 day ago 60% | 1 day ago 85% |
| Advances ODDS (%) | 12 days ago 76% | 3 days ago 85% |
| Declines ODDS (%) | 1 day ago 59% | 1 day ago 69% |
| BollingerBands ODDS (%) | 1 day ago 62% | 1 day ago 89% |
| Aroon ODDS (%) | 1 day ago 68% | 1 day ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AGX’s FA Score shows that 1 FA rating(s) are green while ECG’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AGX’s TA Score shows that 4 TA indicator(s) are bullish while ECG’s TA Score has 5 bullish TA indicator(s).
AGX (@Engineering & Construction) experienced а -12.25% price change this week, while ECG (@Engineering & Construction) price change was -10.16% for the same time period.
The average weekly price growth across all stocks in the @Engineering & Construction industry was -9.01%. For the same industry, the average monthly price growth was -10.47%, and the average quarterly price growth was -31.88%.
AGX is expected to report earnings on Dec 03, 2026.
Engineering & Construction includes companies that engage in non-residential construction and contract services, including ventilation, heating and air conditioning (HVAC) services. The level/value of construction & engineering activity is one of the potentially relevant indicators of the health of businesses, and hence of the overall economy. Some of the large-cap U.S. companies in this industry include Jacobs Engineering Group Inc,, AECOM and Quanta Services, Inc.
A.I.dvisor indicates that over the last year, AGX has been loosely correlated with FIX. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if AGX jumps, then FIX could also see price increases.
A.I.dvisor indicates that over the last year, ECG has been closely correlated with FIX. These tickers have moved in lockstep 79% of the time. This A.I.-generated data suggests there is a high statistical probability that if ECG jumps, then FIX could also see price increases.
| Ticker / NAME | Correlation To ECG | 1D Price Change % | ||
|---|---|---|---|---|
| ECG | 100% | -8.66% | ||
| FIX - ECG | 79% Closely correlated | -6.42% | ||
| EME - ECG | 76% Closely correlated | -5.15% | ||
| PWR - ECG | 75% Closely correlated | -4.83% | ||
| STRL - ECG | 74% Closely correlated | -9.27% | ||
| MYRG - ECG | 68% Closely correlated | -6.64% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CPSY | 25.91 | N/A | N/A |
| Calamos S&P 500 Structured Alt Protection ETF January (CPSY) | |||
| KAMO | 23.79 | -0.07 | -0.29% |
| Kensington Credit Opportunities ETF (KAMO) | |||
| SPXT | 106.20 | -1.81 | -1.68% |
| ProShares S&P 500 Ex-Technology ETF (SPXT) | |||
| BBMC | 114.22 | -3.47 | -2.95% |
| JPMorgan BetaBuilders U.S. Mid Cap Equity ETF (BBMC) | |||
| USAX | 1.11 | -0.25 | -18.08% |
| Tradr 2X Long USAR Daily ETF (USAX) | |||